Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Jairia Dela Cruz, 27 Mar 2020
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.

Bermekimab holds therapeutic potential in hidradenitis suppurativa

03 Mar 2020

Interleukin (IL)-1α inhibition with bermekimab appears to be safe and effective in the treatment of moderate-to-severe hidradenitis suppurativa (HS), inducing clinical response without raising substantial safety concerns, according to the results of a phase II trial.

The trial included 42 HS patients, among whom 24 had previously failed anti-TNF therapy and 18 were anti-TNF naïve. All patients were subcutaneously administered bermekimab at 400 mg weekly (13 doses).

There were no treatment-related adverse events (AEs) recorded except for injection site reactions. A total of 58 nonserious AEs occurred, with most being grade 1 (59 percent) or 2 (36 percent). Two serious AEs were documented (grade 3 fall and grade 3 HS pain), none of which were related to bermekimab, and none led to treatment discontinuation.

In terms of efficacy, 61 percent of patients in the anti-TNF naïve group and 63 percent of those in the anti-TNF failure group achieved HS clinical response after 12 weeks of treatment. There were marked reductions in abscesses and inflammatory nodules seen in 60 percent (p<0.004) and 46 percent (p<0.001) of patients in the respective groups.

Furthermore, those experiencing pain showed clinically and statistically significant pain relief. The Visual Analogue Scale pain score decreased by 64 percent (p<0.001) in the anti-TNF naïve group and by 54 percent (p<0.001) in the anti-TNF failure group.

The present data point to IL-1α inhibition as an important clinical target for skin disease, with bermekimab potentially representing a new therapeutic option for managing moderate-to-severe HS, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Jairia Dela Cruz, 27 Mar 2020
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.